摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(4-溴苯基)磺酰基]-4-甲基哌嗪 | 486422-31-5

中文名称
1-[(4-溴苯基)磺酰基]-4-甲基哌嗪
中文别名
——
英文名称
1-((4-bromophenyl)sulfonyl)-4-methyl-1,4-diazepane
英文别名
1-(4-bromo-benzene-sulfonyl)-4-methyl-[1,4]diazepane;1-(4-bromophenyl)sulfonyl-4-methyl-1,4-diazepane
1-[(4-溴苯基)磺酰基]-4-甲基哌嗪化学式
CAS
486422-31-5
化学式
C12H17BrN2O2S
mdl
MFCD12515248
分子量
333.249
InChiKey
QCAXTVFTVHQJJQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    417.2±55.0 °C(Predicted)
  • 密度:
    1.450±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    49
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:e92eaf15c06d60bdbadc94c18e43dcc6
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery
    摘要:
    Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases, Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzypoxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.
    DOI:
    10.1021/acs.jmedchem.5b00515
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
    [FR] (BENZYL-CYANO-MÉTHYL)-AMIDES SUBSTITUÉS DE L'ACIDE 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE LA CATHÉPSINE C
    摘要:
    本发明涉及2-氮杂-双环[2.2.1]庚烷-3-羧酸(苄基-氰甲基)酰胺的化合物(1)及其作为组织蛋白酶C抑制剂的用途,包含该化合物的药物组合物,以及使用该化合物作为治疗和/或预防与二肽基肽酶I活性相关疾病的方法,例如呼吸系统疾病。
    公开号:
    WO2014140075A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C<br/>[FR] (BENZYL-CYANO-MÉTHYL)-AMIDES SUBSTITUÉS DE L'ACIDE 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE LA CATHÉPSINE C
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014140075A1
    公开(公告)日:2014-09-18
    This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    本发明涉及2-氮杂-双环[2.2.1]庚烷-3-羧酸(苄基-氰甲基)酰胺的化合物(1)及其作为组织蛋白酶C抑制剂的用途,包含该化合物的药物组合物,以及使用该化合物作为治疗和/或预防与二肽基肽酶I活性相关疾病的方法,例如呼吸系统疾病。
  • [EN] IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS<br/>[FR] DERIVES IMIDAZOPYRIDINE SERVANT D'INHIBITEURS DE NO-SYNTHASE INDUCTIBLE
    申请人:ALTANA PHARMA AG
    公开号:WO2005030770A1
    公开(公告)日:2005-04-07
    The compounds of formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.
    式(I)中R1、R2、R3、R4、R5和A的化合物具有描述中给出的含义,是新颖有效的iNOS抑制剂。
  • Arylamines for the treatment of conditions associated with gsk-3
    申请人:Berg Stefan
    公开号:US20060052396A1
    公开(公告)日:2006-03-09
    The present invention relates to new compounds of formula (I) wherein Z, Y, X, P, Q, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , A, m and n are defined as in any one of claims 1 to 3, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds for the treatment of conditions associated with glycogens synthase kinase-3 (GSK3).
    本发明涉及具有公式(I)的新化合物,其中Z、Y、X、P、Q、R、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A、m和n的定义如权利要求1至3中的任意一项,以及制备它们的过程和其中制备的新中间体,含有所述治疗活性化合物的制药配方以及使用所述活性化合物治疗与糖原合酶激酶-3(GSK3)相关的疾病的方法。
  • Imidazopyridine-derivatives as inducible no-synthase inhibitors
    申请人:Ulrich Wolf-Ruediger
    公开号:US20060293302A1
    公开(公告)日:2006-12-28
    The compounds of Formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.
    式(I)中R1、R2、R3、R4、R5和A的含义如说明书所述,这些化合物是新颖有效的iNOS抑制剂。
  • Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
    申请人:Andersson Lars
    公开号:US20090105252A1
    公开(公告)日:2009-04-23
    Compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    该专利涉及式I的化合物,其中R1,R2,R3,R4,R5,R6,R7,R8和R9如规范中所定义,作为基础物质或药物可接受的盐,溶剂或其盐的溶剂,以及制备它们的方法,其中使用了新的中间体,含有所述化合物的制药配方以及在治疗中使用所述化合物的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐